Patents by Inventor Akira Kunitomi

Akira Kunitomi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240060051
    Abstract: Provided is a method for producing naive induced pluripotent stem cells from human somatic cells, comprising the following steps (1) to (3): (1) introducing one or more vectors containing a reprogramming factor into human somatic cells, (2) culturing said somatic cells in the presence of a naive medium, and (3) after step (2), culturing the resulting cells in the presence of the naive medium under the condition in which the amount of the vectors per the somatic cell is reduced to 30% or less of that at the start of step 3.
    Type: Application
    Filed: December 24, 2021
    Publication date: February 22, 2024
    Applicants: Kyoto University, ID PHARMA CO., LTD.
    Inventors: Akira Kunitomi, Tsugumine Shu, Jitsutaro Kawaguchi
  • Publication number: 20230220025
    Abstract: There is provided a quality improving agent for iPS cells, including a polynucleotide, in which the polynucleotide contains an H1foo gene and a regulatory sequence that is capable of regulating at least one of the amount and the period of existence of an H1foo protein expressed from the H1foo gene in cells when the H1foo gene is transduced into the cells.
    Type: Application
    Filed: September 6, 2021
    Publication date: July 13, 2023
    Inventors: Akira Kunitomi, Keiichi Fukuda, Shinsuke Yuasa, Tsugumine Shu
  • Patent number: 10544396
    Abstract: An object of the present invention is to provide an agent for improving quality of an iPS cell, a method for producing an iPS cell, an iPS cell produced by such a method for production, and a composition for producing an iPS cell. The method for producing an iPS cell according to the present invention comprises the step of introducing (a) a nuclear reprogramming substance and (b) an H1foo gene or a gene product thereof into a somatic cell. High-quality iPS cells can be produced in greater quantity by introducing not only a nuclear reprogramming substance but also an H1foo gene or a gene product thereof into a somatic cell.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Heartseed Inc.
    Inventors: Shinsuke Yuasa, Keiichi Fukuda, Akira Kunitomi